Lumixyl(TM) a non-toxic, non-irritating, synthetic peptide technology shown to significantly help improve the appearance of unwanted discoloration, age spots, sun spots and uneven skin tone is now available through select physicians to help their patients achieve picture perfect skin. A hydroquinone alternative, this new cosmeceutical skin brightening cream can be found in leading physician offices for $120 per 1 ounce pump.

Developed by dermatological researchers at Stanford University, Lumixyl's ground-breaking technology is the only peptide shown to measurably promote healthy skin function in restraining tyrosinase, the enzyme responsible for initiating the overproduction of melanin that can cause uneven pigmentation and dark spots.

Lumixyl is created for patients seeking more even skin-tone including those
with:
 --  Melasma
 --  Post-inflammatory hyperpigmentation
 --  Sun spots, age spots or liver spots
 --  Photodamage
 --  Hyperpigmentation caused by systemic disease or prescription drugs

Clinical studies demonstrate that topical use of Lumixyl visibly improves mild to moderate hyperpigmentation with excellent volunteer satisfaction in as little as 8 weeks. Studies show that Lumixyl, a chain of ten amino acids, promoted the moderation of melanin more efficaciously than hydroquinone. At equal concentrations, skin that was treated with the Lumixyl peptide expressed a reduced production of melanin by as much as 40 percent compared to those treated with hydroquinone, which reduced production by only 7 percent in the study.

"The results of studies conducted at Stanford are impressive, showing a 40 percent improvement in melanin related darkening.," commented Nowell Solish, MD, FRCP, Assistant Professor at The University of Toronto, co-director of the Non-Melanoma Skin Cancer clinic at Women's College. "When used as directed, Lumixyl appears to significantly help the skin's ability to diminish dark spots imparting users with brighter, more even skin tone while
limiting irritation, red blotches or even sensitivity to sunlight."

Moreover, in-use and Repeated Insult Patch Testing (RIPT) studies confirm that Lumixyl is safe for topical use and does not elicit irritation or allergic reaction. It does not cause increased sensitivity to sunlight as do many commonly used brightening agents and is gentle for all skin types and tones.

"Hydroquinone has had some controversy in the recent past and this product offers a non-hydroquinone alternative that shows good clinical efficacy in treating discoloration without causing irritation," stated Neil Sadick, MD, FAAD, FAACS, FACP, FACPh.

Lumixyl Topical Brightening Creme can be used alone or if directed by a physician, to compliment other treatments such as Tretinoin, laser resurfacing and SilkPeel(TM), respectively, to diminish dark spots, uneven pigmentation and improve overall skin tone.

Visible Results without Risk
The RIPT results show that, unlike many alternative lightening ingredients, this peptide does not cause irritation or allergic reactions. Lumixyl is formulated to provide the following key advantages:

 --  Non-toxic
 --  Non-irritating
 --  Water-soluble
 --  Safe for all skin types
 --  Produces no harmful by-products
 --  Has no cytotoxic effect

Lumixyl products are made exclusively for dermatologists, plastic surgeons and skin oriented aesthetic physicians. The products are co-marketed in the United States by Basis Medical Technologies and Envy Medical.

About BASIS
BASIS Medical Technologies specializes in the development and distribution of groundbreaking technologies in medicine and medical aesthetics. Headquartered in Toronto, Canada, BASIS is an innovative technology platform with sales, marketing and training capabilities around
the world. With an experienced management team and medical advisory panel, BASIS is committed to delivering and developing cutting-edge medical products internationally. Basis is an exclusive market representative for Lumixyl, a product licensed by Envy Medical Inc..

About Envy Medical
Envy Medical, working through its commercial subsidiary, E Med Inc., develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company's lead products include SilkPeel , a breakthrough device combining exfoliation with dermalinfusion for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing